AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.

Online ovarian Ca resources available.(Gynecology)

OB GYN News

| December 01, 2004 | COPYRIGHT 2004 International Medical News Group. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan.  All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)Copyright

The Gynecologic Cancer Foundation publishes two listing information and support resources for patients with ovarian cancer.

"You Were Just Diagnosed With Ovarian Cancer," which is ...

Related articles from newspapers, magazines, journals, and more
September Is Ovarian Cancer Awareness Month; - Treatment Strategies Provide...
Press release article from: PR Newswire August 19, 2003 700+ words
...women will die from ovarian cancer in 2003 * Roughly...connect you with ovarian cancer experts and patients...Katharine Kinderman, ovarian cancer patient advocate...Sarah Oetgen Ortho Biotech Products, LP SENSEI Health...
New Web Site Provides Comprehensive Information About DOXIL(R) in the Treatment...
Press release article from: PR Newswire April 1, 2003 700+ words
...with recurrent ovarian cancer and their families...sponsored by Ortho Biotech Products, L.P...before." Ovarian cancer is referred...oncology, Ortho Biotech Products, L.P...commitment to the ovarian cancer community by...
Ortho Biotech Announces NDA Submission for Trabectedin for the Treatment of...
Press release article from: PR Newswire November 20, 2008 700+ words
...with relapsed ovarian cancer," said Craig...Nephrology, Ortho Biotech Products, L.P. "We...will die from ovarian cancer in the U.S...marketed by Ortho Biotech Products, L.P. in...development in ovarian cancer and to expand...while Ortho Biotech ...
Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding Trabectedin...
Press release article from: PR Newswire July 15, 2009 700+ words
...the treatment of relapsed ovarian cancer. Ovarian cancer is difficult to treat and...options. Centocor Ortho Biotech Products continues to believe trabectedin...the treatment of recurrent ovarian cancer. The company remains committed...
Phase III Trial of YONDELIS(R) (Trabectedin) Initiated in Ovarian Cancer...
Newspaper article from: PR Newswire Europe April 4, 2005 700+ words
...clinical trial in ovarian cancer patients has been...most common type of ovarian cancer, are not diagnosed...580 new cases of ovarian cancer in the US, and more...division of Ortho Biotech Products, L.P., will...
YONDELIS(R) Granted Orphan Drug Designation by the U.S. FDA For The Treatment...
Newspaper article from: PR Newswire Europe April 7, 2005 700+ words
...the treatment of ovarian cancer. The U.S. application...further development in ovarian cancer together with our...division of Ortho Biotech Products, L.P., will...L.C., Ortho Biotech Products, L.P. and Tibotec...and Orphan Drug for ovarian cancer by the ...
View Current & Future Analysis of the Ovarian Cancer Therapeutics Market.
Press release article from: M2 Presswire August 31, 2006 700+ words
...Therapeutics, Metastatic Ovarian Cancer Therapeutics, and Refractory Ovarian Cancer Therapeutics. The report...Market Overview- Ovarian Cancer- New Therapeutic Approaches...Llc (USA)- Ortho Biotech Products LP (USA)- Ortho Biotech...
CAELYX(TM) and Carboplatin Combination Offers Efficacy and Tolerability in...
Press release article from: PR Newswire June 7, 2004 700+ words
...supported by Schering-Plough. Ovarian Cancer Ovarian cancer is the most deadly of gynecologic...the treatment of advanced ovarian cancer in women who have failed...Therapeutics, a division of Ortho Biotech Products, L.P., a biotechnology...
For more facts and information, see all results
©2009 Gale, a part of Cengage Learning. All rights reserved.
About us | FAQs | Contact us | Privacy policy | Terms and conditions
Other Gale sites: Encyclopedia.com | HighBeam Research | Acquire Content | Books & Authors | Goliath | MovieRetriever | Smart QandA